135 related articles for article (PubMed ID: 27404457)
21. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
22. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
23. Changes in bone mass and bone turnover following ankle fracture.
Ingle BM; Hay SM; Bottjer HM; Eastell R
Osteoporos Int; 1999; 10(5):408-15. PubMed ID: 10591839
[TBL] [Abstract][Full Text] [Related]
24. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
[TBL] [Abstract][Full Text] [Related]
26. The association between insulin-like growth factor I and bone turnover markers in the general adult population.
Niemann I; Hannemann A; Nauck M; Spielhagen C; Völzke H; Wallaschofski H; Friedrich N
Bone; 2013 Sep; 56(1):184-90. PubMed ID: 23792936
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
28. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
29. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
30. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
[TBL] [Abstract][Full Text] [Related]
31. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
Jukkola A; Bloigu R; Holli K; Joensuu H; Valavaara R; Risteli J; Blanco G
Anticancer Res; 2001; 21(4B):2873-6. PubMed ID: 11712779
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic use of bone turnover markers.
Joerger M; Huober J
Recent Results Cancer Res; 2012; 192():197-223. PubMed ID: 22307377
[TBL] [Abstract][Full Text] [Related]
33. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation.
Voorzanger-Rousselot N; Juillet F; Mareau E; Zimmermann J; Kalebic T; Garnero P
Br J Cancer; 2006 Aug; 95(4):506-14. PubMed ID: 16880790
[TBL] [Abstract][Full Text] [Related]
34. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
Hegele A; Wahl HG; Varga Z; Sevinc S; Koliva L; Schrader AJ; Hofmann R; Olbert P
BJU Int; 2007 Feb; 99(2):330-4. PubMed ID: 17092281
[TBL] [Abstract][Full Text] [Related]
35. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
36. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
[TBL] [Abstract][Full Text] [Related]
37. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.
Huang J; Gu T; Ying J
Int J Clin Oncol; 2017 Dec; 22(6):1015-1025. PubMed ID: 28677013
[TBL] [Abstract][Full Text] [Related]
38. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
39. Postoperative expressions of TRACP5b and CA125 in patients with breast cancer and their values for monitoring bone metastasis.
Feng C; Zhan Y; Shao H; Wang Z; Zhu S
J BUON; 2020; 25(2):688-695. PubMed ID: 32521854
[TBL] [Abstract][Full Text] [Related]
40. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study.
Ardawi MS; Maimani AA; Bahksh TA; Rouzi AA; Qari MH; Raddadi RM
Bone; 2010 Oct; 47(4):804-14. PubMed ID: 20659600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
